In his weekly clinical update Dr. Griffin discusses increased acute respiratory illnesses among children and adolescents, estimates of monkeypox incubation period, generation time, and reproduction number, rapid increase in suspected SARS-CoV-2 reinfections, interim infection prevention and control recommendations for healthcare personnel during COVID-19, SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant, breakthrough infection by SARS-CoV-2 delta and omicron variants elicited immune response comparable to mRNA booster vaccination, interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses, further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants, short-course early outpatient Remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the Omicron BA.2 wave, effectiveness of Molnupiravir in high risk patients, and primary care and a distinct symptom pattern for long COVID.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Research assistant position with Amy Rosenfeld (pdf)
• Support MicrobeTV with a Spike t-shirt at Vaccinated.US
• Increase in Acute Respiratory illnesses among children and adolescents (CDC)
• Estimates of Monkeypox incubation period, generation time, reproduction number (CDC)
• Rapid increase in suspected SARS-CoV-2 reinfections (CDC)
• Infection prevention and control recommendations for healthcare providers (CDC)
• SARS-CoV-2 attack rate in vaccinated and unvaccinated household contacts (CDC)
• Breakthrough Infection by variants elicited immune response comparable to vaccine (JID)
• Interval between prior SARS-CoV-2 infection and booster vaccination impacts (CELL)
• Humoral immunity evasion of BA.4 and BA.5 subvariants (The Lancet)
• Outpatient Remdesivir prevents severe disease in organ transplant recipients (Am J Transplant)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury)
• Bebtelovimab fact sheet for providers (FDA)
• Effectiveness of Molnupiravir in high risk patients (CID)
• Update on Long COVID for primary care (BMJ)
• Distinct symptom pattern emerges for COVID-19 long-haul (Scientific Reports)
• Dr. Griffin's treatment guide (pdf)
• Contribute to Floating Doctors fundraiser at PWB
• Letters read on TWiV 941
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]